Clinical Trials

30 enrolled

Phase 2 Active not recruiting

Stomach Neoplasms

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

30 enrolled

Advanced Biliary Tract Carcinoma

NCT07165847 2025-09-10

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

40 enrolled

Phase 2 Not yet recruiting

Stomach Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

10 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT06988956 2025-05-25

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

95 enrolled

Esophageal Squamous Cell Carcinoma

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

66 enrolled

Fruquintinib

NCT04260269 2024-12-12

CardioSwitch

Enrolling by invitation

200 enrolled

Solid Tumor

NCT03175679 2024-09-19

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Phase 1 Completed

10 enrolled 14 charts

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT06603974 2024-09-19

EASOBFGE

48 enrolled

Stomach Neoplasms

NCT06354140 2024-07-17

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

45 enrolled

Phase 4 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT05498766 2024-06-24

Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients

702 enrolled

Phase 2 Not yet recruiting

Stomach Neoplasms

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

42 enrolled

Phase 2 Not yet recruiting

HER2-positive Gastric Cancer

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

120 enrolled

Efficacy and Safety

NCT06361316 2024-04-11

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Phase NA Recruiting

53 enrolled

Pancreatic Neoplasms

NCT06339619 2024-04-01

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

32 enrolled

Esophageal Squamous Cell Carcinoma

NCT06187597 2024-03-12

EC-CRT-007

140 enrolled

Esophageal Squamous Cell Carcinoma

NCT05325528 2023-02-01

Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases

Phase 2/3 Unknown

40 enrolled

Stomach Neoplasms

NCT05594381 2022-10-26

A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.

90 enrolled

Stomach Neoplasms

NCT05529355 2022-09-07

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04856761 2022-08-18

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

Unknown

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Cholangiocarcinoma

NCT03162510 2022-04-07

SOLAR

Phase 1 Completed

18 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT05070598 2021-10-07

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

35 enrolled

HER2-positive Gastric Cancer

NCT03154983 2020-12-09

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

48 enrolled

Stomach Neoplasms

NCT04216758 2020-06-30

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

300 enrolled

Stage IA Pancreatic Adenocarcinoma

NCT00207831 2020-03-25

UFT RT Phase 3

Phase 3 Terminated

219 enrolled

Rectal Neoplasms

NCT04135781 2020-03-23

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Phase 3 Unknown

616 enrolled

Phase 1/2 Not yet recruiting

Stomach Neoplasms

NCT04310774 2020-03-19

CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer

200 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04202484 2019-12-17

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

20 enrolled

Stomach Neoplasms

NCT03941561 2019-05-31

S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）

Phase 3 Recruiting

1,006 enrolled

Stomach Neoplasms

NCT03121313 2019-02-12

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

68 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

NCT03475615 2018-03-23

A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites

Phase 3 Unknown

215 enrolled

Stomach Neoplasms

NCT03175705 2018-01-18

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Phase 1 Unknown

18 enrolled

Carcinoma, Hepatocellular

NCT02527785 2017-08-23

Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer

44 enrolled

Stomach Neoplasms

NCT02836977 2017-02-08

Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection

Phase NA Unknown

400 enrolled

Colonic Neoplasms

NCT02447679 2017-02-07

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

40 enrolled

Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions

NCT02943252 2016-10-24

The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

30 enrolled

Head & Neck

Head and Neck Neoplasms

NCT01050426 2016-10-14

PERU

Phase 2 Terminated

17 enrolled

Pancreatic Neoplasms

NCT02903498 2016-10-12

The Maintenance Treatment of UFT in Advanced Gastric Cancer

58 enrolled

Stomach Neoplasms

NCT00392899 2016-09-28

Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery

Phase 3 Completed

2,025 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00898846 2016-09-28

Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery

Completed

1,111 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00660894 2016-08-03

Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

Phase 3 Completed

1,535 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT02623153 2015-12-07

Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer

200 enrolled

Stomach Neoplasms

NCT01262274 2015-05-21

Neo-ACET BC

Phase 2 Terminated

57 enrolled

Breast

Breast Neoplasms

NCT02280070 2014-10-31

RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

110 enrolled

Rectal Neoplasms

NCT02090153 2014-03-18

Study of S-1 Plus LV for Advanced Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT00009815 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Unspecified Adult Solid Tumor, Protocol Specific

NCT00009828 2013-12-19

Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors

Phase 1 Withdrawn

Unspecified Adult Solid Tumor, Protocol Specific

NCT00003925 2013-04-08

Combination Chemotherapy In Treating Patients With Advanced Cancer

Phase 1 Completed

36 enrolled